Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 8/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8574855 | 0.82 | SPR (0.61) | SPRPOLBCCR2CCR5NR3C1 | |
| SCHEMBL5070874 | 0.81 | SPR (0.61) | SPRPOLBCCR2CCR5NR3C1 | |
| SCHEMBL5961520 | 0.76 | SPR (0.60) | SPRPOLBCCR2CCR5LMNA | |
| SCHEMBL7553541 | 0.76 | SPR (0.60) | SPRPOLBCCR2CCR5NR3C1 | |
| SCHEMBL20413616 | 0.76 | SPR (0.59) | SPRPOLBCCR2CCR5NR3C1 | |
| SCHEMBL17980518 | 0.74 | NR3C1 (0.71) | SPRPOLBCCR2CCR5NR3C1 | |
| SCHEMBL7079541 | 0.73 | CCR2 (0.68) | SPRPOLBCCR2CCR5NR3C1 | |
| SCHEMBL17980531 | 0.72 | NR3C1 (0.57) | SPRPOLBCCR2CCR5NR3C1 | |
| SCHEMBL5961483 | 0.72 | CCR2 (0.66) | SPRPOLBCCR2CCR5NR3C1 | |
| SCHEMBL17980879 | 0.72 | CCR2 (0.63) | SPRPOLBCCR2CCR5NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345180-B2 | Compound inhibiting dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2008-03-18 | — | — | US | disclosed |
| US-20060229286-A1 | Compound inhibiting dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| EP-1595866-A1 | COMPOUND INHIBITING DIPEPTIDYL PEPTIDASE IV | Sanwa Kagaku Kenkyusho Co., Ltd. (JP) | 2005-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229286-A1 | Compound inhibiting dipeptidyl peptidase IV | DPP4, DPP3, DPP7 | SPR 121/4885POLB 4293/4885CCR2 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.